perhexiline has been researched along with Heart Disease, Ischemic in 12 studies
Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Perhexiline treatment also increased resting and peak dobutamine stress regional myocardial function (by 15% and 24%, respectively) and normalized skeletal muscle phosphocreatine recovery after exercise." | 6.71 | Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. ( Ashrafian, H; Campbell, R; Clarke, K; Fraser, AG; Frenneaux, M; Gunaruwan, P; Horowitz, J; Lee, L; Scheuermann-Freestone, M; Taylor, R; Williams, L, 2005) |
| "Rationale for treatment with perhexiline included myocardial ischemia in 88% and severe systolic heart failure in 38%." | 3.83 | Can Perhexiline Be Utilized Without Long-Term Toxicity? A Clinical Practice Audit. ( Choi, BY; Chong, CR; Horowitz, JD; Phuong, H; Raman, B, 2016) |
| "Perhexiline treatment also increased resting and peak dobutamine stress regional myocardial function (by 15% and 24%, respectively) and normalized skeletal muscle phosphocreatine recovery after exercise." | 2.71 | Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. ( Ashrafian, H; Campbell, R; Clarke, K; Fraser, AG; Frenneaux, M; Gunaruwan, P; Horowitz, J; Lee, L; Scheuermann-Freestone, M; Taylor, R; Williams, L, 2005) |
| "In a prospective study, steady-state plasma concentrations of (+) and (-)-perhexiline were quantified in 10 CYP2D6 genotyped patients following dosing with 100 mg/day rac-perhexiline maleate, and following a subsequent dosage increase to 150 or 200 mg/day." | 1.34 | Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia. ( Coller, JK; Davies, BJ; Herbert, MK; Horowitz, JD; Inglis, SC; James, HM; Milne, RW; Morris, RG; Sallustio, BC; Somogyi, AA, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ceccarelli, SM | 1 |
| Chomienne, O | 1 |
| Gubler, M | 1 |
| Arduini, A | 1 |
| Phuong, H | 1 |
| Choi, BY | 1 |
| Chong, CR | 1 |
| Raman, B | 1 |
| Horowitz, JD | 6 |
| Jawad, E | 1 |
| Arora, R | 1 |
| Noble, MI | 1 |
| Drake-Holland, AJ | 1 |
| Bansal, M | 1 |
| Chan, J | 1 |
| Leano, R | 1 |
| Pillans, P | 1 |
| Horowitz, J | 3 |
| Marwick, TH | 1 |
| Chirkov, YY | 1 |
| Kennedy, JA | 2 |
| Sverdlov, AL | 1 |
| Lee, L | 2 |
| Frenneaux, M | 2 |
| Campbell, R | 1 |
| Scheuermann-Freestone, M | 1 |
| Taylor, R | 1 |
| Gunaruwan, P | 1 |
| Williams, L | 1 |
| Ashrafian, H | 2 |
| Fraser, AG | 1 |
| Clarke, K | 1 |
| Davies, BJ | 2 |
| Coller, JK | 2 |
| James, HM | 2 |
| Somogyi, AA | 2 |
| Sallustio, BC | 2 |
| Inglis, SC | 1 |
| Herbert, MK | 1 |
| Morris, RG | 1 |
| Milne, RW | 1 |
| Frenneaux, MP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery[NCT00845364] | Phase 2/Phase 3 | 290 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy[NCT00989508] | Phase 2/Phase 3 | 220 participants (Anticipated) | Interventional | 2009-10-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for perhexiline and Heart Disease, Ischemic
| Article | Year |
|---|---|
Chronic stable angina pectoris.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetanilides; Angina Pectoris; Antihypertensive Agent | 2008 |
Modulation of myocardial metabolism: an emerging therapeutic principle.
Topics: Acetanilides; Amiodarone; Cardiovascular Agents; Heart Failure; Humans; Hypertrophy, Left Ventricula | 2010 |
Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Cardiovascular Agents; Drug Therapy, Com | 2004 |
Perhexiline.
Topics: Angina Pectoris; Animals; Aortic Valve Stenosis; Calcium Channel Blockers; Carnitine O-Palmitoyltran | 2007 |
Perhexiline.
Topics: Angina Pectoris; Animals; Aortic Valve Stenosis; Calcium Channel Blockers; Carnitine O-Palmitoyltran | 2007 |
Perhexiline.
Topics: Angina Pectoris; Animals; Aortic Valve Stenosis; Calcium Channel Blockers; Carnitine O-Palmitoyltran | 2007 |
Perhexiline.
Topics: Angina Pectoris; Animals; Aortic Valve Stenosis; Calcium Channel Blockers; Carnitine O-Palmitoyltran | 2007 |
2 trials available for perhexiline and Heart Disease, Ischemic
| Article | Year |
|---|---|
Effects of perhexiline on myocardial deformation in patients with ischaemic left ventricular dysfunction.
Topics: Aged; Cardiotonic Agents; Cardiovascular Agents; Dobutamine; Echocardiography; Exercise Test; Female | 2010 |
Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.
Topics: Aged; Cardiovascular Agents; Chronic Disease; Echocardiography, Stress; Fatty Acids; Female; Glucose | 2005 |
6 other studies available for perhexiline and Heart Disease, Ischemic
| Article | Year |
|---|---|
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
Topics: Animals; Carnitine; Carnitine O-Palmitoyltransferase; Catalytic Domain; Diabetes Mellitus, Type 2; E | 2011 |
Can Perhexiline Be Utilized Without Long-Term Toxicity? A Clinical Practice Audit.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Drug Monitoring; Female; Follow-Up Studies; Heart Fa | 2016 |
Lack of effect of perhexiline in ischaemic heart failure.
Topics: Cardiovascular Agents; Humans; Myocardial Ischemia; Perhexiline; Treatment Failure | 2010 |
The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia.
Topics: Aged; Aged, 80 and over; Alleles; Cardiovascular Agents; Cytochrome P-450 CYP2D6; Gene Frequency; Ge | 2006 |
Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia.
Topics: Biological Availability; Cardiovascular Agents; Cytochrome P-450 CYP2D6; Genotype; Humans; Metabolic | 2007 |
Effect of trimetazidine on carnitine palmitoyltransferase-1 in the rat heart.
Topics: Amiodarone; Animals; Carnitine O-Palmitoyltransferase; Dose-Response Relationship, Drug; In Vitro Te | 1998 |